Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease.
Adalimumab (ADA) trough level and anti-ADA antibody (AAA) positivity influence mucosal healing and loss of response in patients with inflammatory bowel disease (IBD). In this study, we clarified the correlation between ADA monitoring, including non-trough level, and real-world IBD clinical outcomes....
Guardado en:
Autores principales: | Masaichi Kato, Ken Sugimoto, Kentaro Ikeya, Ryosuke Takano, Ai Matsuura, Takahiro Miyazu, Natsuki Ishida, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Takahisa Furuta, Hiroyuki Hanai |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7bcc3f90536f46b3bb7962457b2aa47e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis
por: Natsuki Ishida, et al.
Publicado: (2021) -
C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis
por: Natsuki Ishida, et al.
Publicado: (2021) -
Prevalence of UL97 gene mutations and polymorphisms in cytomegalovirus infection in the colon associated with or without ulcerative colitis
por: Satoshi Tamura, et al.
Publicado: (2021) -
Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
por: Satoshi Tamura, et al.
Publicado: (2020) -
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Linda Cingolani, et al.
Publicado: (2021)